Pharmaceutical

Datavant, Premier Inc, Privacy Analytics to Showcase Privacy Enhancing Technologies in Healthcare at Congressional Briefing

NEW YORK, July 29, 2024 /PRNewswire/ -- Datavant, the leading health data platform company, is proud to announce its participation in…

1 year ago

Prescription Digital Therapeutics (PDT) Market Expected to Grow at a CAGR of 22.41% from 2024 to 2031 | Exclusive Report by InsightAce Analytic Pvt. Ltd

JERSEY CITY, N.J., July 29, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report…

1 year ago

New Research Supports PillSafe’s Methodology in Reducing the Risk of Medication Misuse and Overuse

The study raises concerns that overprescribing medications and the resulting unused medication are drivers of opioid misuse.EDMOND, OK / ACCESSWIRE…

1 year ago

Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in AI-powered precision cardiovascular medicine, today announced the launch of its…

1 year ago

Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in AI-powered precision cardiovascular medicine, today announced the launch of its…

1 year ago

Parexel Releases 2023 Environmental, Social and Governance Report

DURHAM, N.C., July 29, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the…

1 year ago

Veru to Participate in the BTIG Virtual Biotechnology Conference

MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

1 year ago

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis…

1 year ago

Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients

XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment-naïve patients, enabling them to go…

1 year ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory…

1 year ago